In this work, ST2 deficiency abolished the effects of IL-33 treatment on hepatic steatosis and fibrosis, so we might also conclude that the function of IL-33 in NASH mice was dependent on ST2 signaling. The gene discussed is IL33; the disease is metabolic dysfunction-associated steatohepatitis.